3,968 results match your criteria: "Liver Center[Affiliation]"

Article Synopsis
  • Givosiran is an RNA interference drug approved to treat acute hepatic porphyria, particularly acute intermittent porphyria, and this study examined its long-term safety and efficacy over a follow-up period of up to 48 months.* -
  • Sixteen participants, aged 18-65, were monitored for adverse events, changes in specific biomarker levels, rates of porphyria attacks, and quality of life; common side effects included abdominal pain and nausea.* -
  • Results showed a significant reduction in porphyria attacks (97%) and hemin usage (96%), with all patients free from major attacks after 33 months, along with notable improvements in urinary biomarkers and quality of life.*
View Article and Find Full Text PDF

Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between different causes of acute kidney injury requiring renal replacement therapy (AKI-RRT) and mortality in hospitalized patients with cirrhosis.
  • Conducted across multiple U.S. hospitals in 2019, the research included 2,063 patients, finding that 18.1% underwent AKI-RRT.
  • Results indicate that while patients with hepatorenal syndrome (HRS-AKI) received different treatment approaches compared to those with other causes of AKI, there was no significant difference in 90-day mortality risk between the two groups.
View Article and Find Full Text PDF
Article Synopsis
  • A study aimed to investigate the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression to advanced fibrosis in individuals aged 60 and older, revealing a growing concern as this population expands.* -
  • Researchers analyzed data from 329,388 seniors, finding an overall MASLD incidence rate of 1.94 per 100 person-years, which increased significantly in people who were overweight or obese.* -
  • The results highlight that overweight/obesity is a strong predictor for both MASLD and advanced fibrosis in older adults, emphasizing the need to identify age-specific risk factors for better health outcomes in this demographic.*
View Article and Find Full Text PDF
Article Synopsis
  • The study explored the link between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of kidney cancer, noting that both conditions are on the rise due to metabolic health issues.
  • Researchers examined over 8 million participants aged 20-79, finding that those with MASLD or increased alcohol uptake (MetALD) had significantly higher chances of developing kidney cancer.
  • The association was particularly strong in younger individuals, suggesting a need for increased focus on metabolic health in this age group to potentially mitigate kidney cancer risks.
View Article and Find Full Text PDF
Article Synopsis
  • MRI biomarkers like iron corrected T1 (cT1) and liver fat content (LFC) are promising noninvasive alternatives to liver biopsies, showing potential associations with liver disease improvement.
  • A study analyzed data from 150 participants in clinical trials, revealing that responders (those who had a resolution of steatohepatitis) demonstrated significantly greater reductions in cT1 and LFC compared to non-responders.
  • These findings suggest that significant changes in these MRI markers can help predict histological improvements in liver health following treatment, highlighting their potential utility in clinical settings.
View Article and Find Full Text PDF

Activated mTORC2/AKT signaling plays a role in hepatocellular carcinoma (HCC). Research has shown that TSC/mTORC1 and FOXO1 are distinct downstream effectors of AKT signaling in liver regeneration and metabolism. However, the mechanisms by which these pathways mediate mTORC2/AKT activation in HCC are not yet fully understood.

View Article and Find Full Text PDF
Article Synopsis
  • A study in Korea assessed the safety and effectiveness of lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma, with a focus on adverse drug reactions (ADRs) and treatment outcomes.
  • Out of 658 patients treated with lenvatinib, 57.8% experienced ADRs, while 13.5% had severe ADRs (grade ≥3), including 1.2% reporting both asthenia and hepatic encephalopathy as the most common severe reactions.
  • The study found that 1.0% of patients had a complete response, 12.9% a partial response, and 45.2%
View Article and Find Full Text PDF

Background & Aims: We investigated the association of physical activity (PA) levels and changes with the risk of hepatocellular carcinoma (HCC) in patients with type 2 diabetes.

Methods: Patients with type 2 diabetes who had undergone health examinations in 2009 and 2011 were enrolled. In total, 1,439,152 patients were included in the analysis.

View Article and Find Full Text PDF

Background: This study aimed to examine whether repeated measurements on noninvasive fibrosis scores during follow-up improve long-term nonalcoholic fatty liver disease (NAFLD) outcome prediction.

Methods: A cohort study of 2,280 NAFLD patients diagnosed at the Seoul National University Hospital from 2001 to 2015 was conducted. Multivariable Cox regression models with baseline and designated time-point measurements of the fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) were used to assess the association between these scores and overall mortality, liver-related outcomes, and cardiovascular events.

View Article and Find Full Text PDF

AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment.

J Hepatol

September 2024

Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea. Electronic address:

Article Synopsis
  • Direct-acting antivirals (DAAs) have improved treatment for chronic hepatitis C (HCV), but there is a lack of focus on the risk of liver-related events (LREs) after achieving sustained virological response (SVR), which this study aims to address with the AI-Safe-C score.
  • The AI-Safe-C score, developed using data from 913 non-cirrhotic HCV patients, assesses the risk of LREs by considering factors like liver stiffness measurement (LSM), age, and sex, showing high prediction accuracy in validation cohorts from Korea, Hong Kong, and France.
  • This score is essential for identifying non-cirrhotic patients at risk of developing LREs
View Article and Find Full Text PDF
Article Synopsis
  • Recent advancements in ultrasound elastography (UE) and ultrasound attenuation imaging (UA) allow for better detection of liver fibrosis and steatosis in patients with steatotic liver disease (SLD), which is common globally.
  • A survey conducted among 275 medical facilities in Saga Prefecture revealed a 56% response rate, showing that most facilities recognized the importance of UE and UA for liver conditions, but actual usage was low (21% for UE and 12% for UA).
  • The study concluded that despite the importance of these imaging techniques in liver cancer surveillance, awareness and availability of UE and UA in these facilities are lacking given the high prevalence of SLD.
View Article and Find Full Text PDF

Dynamic allostery drives autocrine and paracrine TGF-β signaling.

Cell

October 2024

Department of Biochemistry and Biophysics, University of California, San Francisco (UCSF), San Francisco, CA, USA; Howard Hughes Medical Institute, UCSF, San Francisco, CA, USA. Electronic address:

Article Synopsis
  • TGF-β is a crucial protein involved in development and immunity, usually expressed in a latent form associated with its prodomain and presented on immune cells via GARP.
  • Recent findings indicate that TGF-β can signal without needing to fully dissociate from its latent form, challenging existing beliefs.
  • New research using advanced microscopy shows that the binding of integrin αvβ8 can alter the structure of latent TGF-β, allowing it to activate signaling pathways without being released, and this mechanism may apply to other similar receptor/ligand systems.
View Article and Find Full Text PDF
Article Synopsis
  • - The study aimed to create and validate a prognostic model for assessing the risk of hepatocellular carcinoma (HCC) in noncirrhotic adults with chronic hepatitis B, focusing on those without significant alanine aminotransferase (ALT) elevation.
  • - Researchers analyzed data from over 13,000 patients across several cohorts in Taiwan, Korea, and Hong Kong, finding that baseline HBV DNA levels were key predictors of HCC risk, especially at moderate viral loads.
  • - The new model, called Revised REACH-B, showed strong predictive accuracy and was more beneficial compared to other strategies in predicting HCC risk, though its applicability to other racial groups remains a limitation.
View Article and Find Full Text PDF

Background: Prenatally diagnosed hepatic hilar cysts are a challenging finding for the clinician. They can either be a sign of cystic biliary atresia (BA) or a choledochal cyst (CC), two diagnoses with different postnatal management and prognosis. Based on a case report of four patients, we aim to propose a management algorithm for prenatally diagnosed "hepatic hilar cysts".

View Article and Find Full Text PDF
Article Synopsis
  • Tumor neoantigen peptide vaccines have great potential to enhance cancer immunotherapy, but effectively delivering these peptides and adjuvants to immune cells is a challenge.
  • A new protein carrier called eVLP is designed using mammalian-derived PEG10, which organizes into virus-like particles for improved delivery and immune response stimulation.
  • The engineered vaccine, ePAC, packages neoantigens into eVLP and is modified to target dendritic cells, showing strong antitumor effects in mouse cancer models when paired with anti-TIM-3, indicating its potential for clinical use.
View Article and Find Full Text PDF

Interactions between adipose tissue, liver and immune system are at the center of metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. To address the need for an accurate in vitro model, we establish an interconnected microphysiological system (MPS) containing white adipocytes, hepatocytes and proinflammatory macrophages derived from isogenic human induced pluripotent stem cells. Using this MPS, we find that increasing the adipocyte-to-hepatocyte ratio moderately affects hepatocyte function, whereas macrophage-induced adipocyte inflammation causes lipid accumulation in hepatocytes and MPS-wide insulin resistance, corresponding to initiation of metabolic dysfunction-associated steatotic liver disease.

View Article and Find Full Text PDF

Epidemiology of Chronic Hepatitis B Virus Infection, Alameda County, California, 2017-2021.

J Public Health Manag Pract

January 2025

Author Affiliations: Alameda County Public Health Department (Dr Yette, Ms Marusinec, and Drs Conlon and Chitnis), Division of Communicable Disease Control and Prevention, San Leandro, CA; Asian Liver Center, Department of Surgery (Drs Pham, Toy, and So), Division of Gastroenterology and Hepatology (Dr Wong), Stanford University School of Medicine, Palo Alto, CA; and Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA (Dr Wong).

Context: In the United States, chronic hepatitis B (CHB) virus infection predominantly affects ethnic minorities and vulnerable populations.

Objective: We analyzed surveillance data to describe CHB epidemiology to guide hepatitis B virus (HBV) elimination efforts in Alameda County.

Design: Persons with CHB during 2017-2021 were identified by ≥2 positive HBV tests (ie, HBsAg, HbeAg, and HBV DNA) ≥180 days apart using data from California Reportable Disease Information Exchange.

View Article and Find Full Text PDF

Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.

Gastroenterology

September 2024

Liver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, Connecticut. Electronic address:

A consistent feature of chronic liver diseases and the hallmark of pathologic repair is the so-called "ductular reaction." This is a histologic abnormality characterized by an expansion of dysmorphic cholangiocytes inside and around portal spaces infiltrated by inflammatory, mesenchymal, and vascular cells. The ductular reaction is a highly regulated response based on the reactivation of morphogenetic signaling mechanisms and a complex crosstalk among a multitude of cell types.

View Article and Find Full Text PDF

Aims: Cardiovascular disease (CVD) is a common cause of death in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, CVD surveillance is important, but it is not well established. We evaluated the association between liver fibrosis, carotid artery atherosclerosis, and coronary artery stenosis in patients with MASLD.

View Article and Find Full Text PDF

Adeno-associated virus-based gene therapy (valoctocogene roxaparvovec) is an attractive treatment for hemophilia A. Careful clinical management is required to minimize the risk of hepatotoxicity, including assessment of baseline liver condition to determine treatment eligibility and monitoring liver function after gene therapy. This article describes recommendations (developed by a group of hemophilia experts) on hepatic function monitoring before and after gene therapy.

View Article and Find Full Text PDF
Article Synopsis
  • There is a significant lack of data on dialysis decision-making for patients with cirrhosis who are ineligible for transplants, prompting this study to explore RRT initiation processes, predictors, and outcomes.
  • The research involved evaluating 372 patients with acute kidney injury due to conditions like hepatorenal syndrome, revealing that those who received RRT had a median survival of 12.5 days, compared to just 2 days for those who didn't.
  • The study highlights that most patients receiving RRT had short-term mortality and intensive end-of-life care, and it emphasizes the need for better clinical processes for communication and decision-making regarding RRT in this vulnerable population.
View Article and Find Full Text PDF